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RECQ1 is the most abundant member of the human RecQ family of DNA helicases
genetically linked with cancer predisposition syndromes and well known for their
functions in genome stability maintenance through DNA repair. Despite being the first
discovered RecQ homolog in humans, biological functions of RECQ1 have remained largely
underappreciated and its relevance to cellular transformation is yet unclear. RECQ1 is
overexpressed and amplified in many clinical cancer samples. In silico evaluation of RECQ1
mRNA expression across the NCI-60 cancer cell lines predicts an association of RECQ1
with cancer cell migration, invasion, and metastasis. Consistent with this, latest work
implicates RECQ1 in regulation of gene expression, especially of those associated with
cancer progression. Functionally, silencing RECQ1 expression significantly reduces cell
proliferation, migration, and invasion. Collectively, these results propose that discerning
the role of RECQ1 in conferring proliferative and invasive phenotype to cancer cells could
be useful in developing therapeutic strategies to block primary tumor progression and
metastasis.
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INTRODUCTION
The RecQ helicase family is a group of highly conserved DNA
unwinding enzymes described as caretakers of the genome
(Hickson, 2003; Brosh, 2013; Croteau et al., 2014). In humans,
RECQ1, also known as RECQL or RECQL1, is the most abun-
dant member of the RecQ helicase family represented by five
homologs: RECQ1, WRN, BLM, RECQL4, and RECQL5 (Sharma
and Brosh, 2008). Loss of function of three of the five members
of the RecQ family are genetically linked with rare cancer sus-
ceptibility syndromes (Werner syndrome, Bloom syndrome, and
Rothmund–Thomson syndrome) but the association of RECQ1
with cellular transformation is yet unclear. The five human RecQ
helicases are expected to exhibit some functional redundancy, but
the fact that the functional loss of one homolog cannot be substi-
tuted by others clearly indicates critical specialized functions.
RECQ1 is an integral component of replication complex
in unperturbed cells and implicated in maintaining replica-
tion fork progression (Thangavel et al., 2010). Mechanistically,
RECQ1 helicase binds and preferentially unwinds structural
intermediates of DNA replication and repair, such as forked
duplexes, D-loops, and Holliday junctions; and also exhibits an
intrinsic ability to promote annealing of complementary single
strand DNA (Sharma et al., 2005; Popuri et al., 2008). RECQ1-
deficient cells are characterized by spontaneously elevated sister
chromatid exchanges (Sharma and Brosh, 2008) that represent
non-productive attempts to restart replication (Helleday, 2003).
Furthermore, RECQ1-deficient cells accumulate DNA damage,
display increased sensitivity to DNA damaging agents that induce
stalled and collapsed replication forks, and exhibit chromosomal
instability (Sharma and Brosh, 2007, 2008; Sharma et al., 2007).
Thus it is believed that RECQ1 acts to restore productive DNA
replication following stress and prevents subsequent genomic
instability (Sharma and Brosh, 2008; Popuri et al., 2012; Berti
et al., 2013; Sami and Sharma, 2013). RECQ1-deficiency is tol-
erated by cells to repair I-Sce induced double strand breaks by
homologous recombination (Sharma et al., 2012), but a role of
RECQ1 in replication stress induced recombination is possible
given the demonstrated activity of RECQ1 protein to dissociate
native Rad51-bound D-loops by branch migration (Branzei and
Foiani, 2007; Bugreev et al., 2008).
Human RECQ1 is ubiquitously expressed in all cell types
regardless of cell cycle stage (Kawabe et al., 2000). Previous studies
have shown that RECQ1 is upregulated in rapidly dividing cells
and its expression is higher in many cancer cell lines as compared
to normal cells (Kawabe et al., 2000; Futami et al., 2008a). A
meta-analyses of gene expression pattern included RECQ1 among
the common signature genes for cancer as defined by the Gene
Ontology Consortium (Xu et al., 2007). We noted that RECQ1
is overexpressed and amplified in many clinical cancer samples1.
Forty three out of 447 differential expression analyses included
RECQ1 in the top 10% upregulation list while only two did in the
top 10% downregulation list in cancer versus normal2. Indeed,
overexpression of RECQ1 has been experimentally demonstrated
in human glioblastoma (Mendoza-Maldonado et al., 2011), ovar-
ian cancer (Sanada et al., 2013), and head and neck squamous cell
carcinoma (Arai et al., 2011). Furthermore, RECQ1 protein levels
correlated with histological grade and Ki-67 labeling index in hep-
atocellular carcinoma (Futami et al., 2010) and high proliferative
potential in ovarian cancer (Sanada et al., 2013). A polymorphism
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in RECQ1, A159C, has been associated with faster tumor pro-
gression and significantly reduced survival of pancreatic adeno-
carcinoma patients that received gemcitabine and radiotherapy
(Li et al., 2006; Cotton et al., 2009). The A159C SNP is located
in the 3′UTR and, thus, may functionally alter RECQ1 expression
and affect clinical outcome. Remarkably, RECQ1 silencing signifi-
cantly reduced proliferation of cancer cells as compared to normal
cells in cell culture models and also suppressed tumor growth in
mouse xenograft models (Sharma and Brosh, 2007; Futami et al.,
2008a,b, 2010; Arai et al., 2011; Mendoza-Maldonado et al., 2011).
Tumor cell growth was significantly inhibited in vitro by silencing
RECQ1 in hypopharyngeal carcinoma cells and the combination
treatment of RECQ1 siRNA and cis-platinum (II) diammine
dichloride significantly augmented the in vivo anticancer effects of
the drug (Arai et al., 2011). Dysfunctional checkpoint status, e.g.,
p53 in cancer cells may be linked to mitotic catastrophe following
RECQ1 silencing (Futami et al., 2008a) but the ability of RECQ1
to facilitate recovery from replication stress could also be espe-
cially important for cancer cells (Popuri et al., 2012; Berti et al.,
2013; Lu et al., 2013). Although these studies imply an association
of RECQ1 with tumor growth, progression or differentiation,
the molecular mechanisms through which RECQ1 might support
malignant progression are not understood.
Recent analysis of genome-wide changes in gene expression
has revealed a novel involvement of RECQ1 in regulation of
gene expression in addition to its role in DNA damage repair (Li
et al., 2014). Besides cell proliferation, the top 10 over-represented
processes also included cellular movement and cell morphology
suggesting that RECQ1 enhances the expression of multiple genes
that play key roles in cell migration, invasion, and metastasis,
including EZR, ITGA2, ITGA3, ITGB4, SMAD3, and TGFBR2.
Functionally, silencing RECQ1 significantly reduced migration
and invasion of the highly invasive MDA-MB-231 breast cancer
cells indicating that RECQ1 plays a role in enhancing cell migra-
tion and invasion (Li et al., 2014). Consistent with the results
from in vitro cell culture based study, high RECQ1 expression
significantly associated (P = 4.2E-06) with poor overall survival
in breast cancer in TCGA dataset (Gyorffy et al., 2010). High
expression of RECQL4 was also associated with poor survival
in breast cancer but the expression levels of WRN, BLM, and
RECQL5 did not correlate with survival (Li et al., 2014).
A putative role in regulation of gene expression has been
suggested by studies in Neurospora where a RECQ1 homolog
mediates posttranscriptional gene silencing (Cogoni and Macino,
1999). Remarkably, rat RECQ1 was identified in a piRNA pro-
tein complex important for gene silencing (Lau et al., 2006),
raising the possibility that human RECQ1 may function in a
conserved mechanism. Although the mechanism of gene reg-
ulation by RECQ1 is yet unknown, the promoters of genes
downregulated upon RECQ1 silencing were significantly enriched
for a potential G4 sequence motif which are associated with
potential to form G-quadruplex structures in DNA (G4 DNA;
Li et al., 2014). Chromatin immunoprecipitation experiments
demonstrated RECQ1 binding to G4 sequence motifs in the
promoters of select downregulated genes indicating that RECQ1
may modulate gene expression by regulating the in vivo stability of
G4 DNA structures. Elegant studies from the Maizels (Gray et al.,
2014), Monnat and Harris (Nguyen et al., 2014) labs have recently
identified that gene regulatory functions of XPB, XPD, and BLM
helicases also involve G4 DNA suggesting that the binding to G4
motifs may be a common mechanism of transcriptional regula-
tion by these distinct DNA helicases. Importantly, similar to XPB,
but unlike BLM, RECQ1 binds but does not unwind G4 DNA in
vitro (Popuri et al., 2008; Sharma, 2011). It is likely that binding
to specific G4 sequence motifs by each of these helicases may
characterize specific signaling and regulatory pathways associated
with cancer. In addition to gene regulatory regions, G4 sequence
motifs are also present at chromatin regions preferentially bound
by RECQ1 such as replication origins, fragile sites, and telomeres
indicating that RECQ1 functions are especially critical at genomic
loci having potential to form secondary structures (Thangavel
et al., 2010; Lu et al., 2013; Maizels and Gray, 2013; Popuri et al.,
2014).
RECQ1 EXPRESSION ACROSS THE NCI-60 HUMAN TUMOR
CELL LINES
By virtue of its overexpression in cancer and its association with
cell proliferation, migration, and invasion, RECQ1 can potentially
serve as a predictive biomarker and attractive target for cancer
therapy. To assess gene expression pattern of RECQ1 in various
tumors, we utilized a panel of 60 human tumor cell lines derived
from nine different tissues of origin (NCI-60) that has been exten-
sively characterized for gene expression and copy-number varia-
tions, and commonly used for genetic analysis and screening of
potential chemotherapeutic agents (Shoemaker, 2006; Weinstein,
2006; Liu et al., 2010). We conducted in silico analysis of RECQ1
expression pattern across the NCI-60 employing a publicly acces-
sible webtool CellMiner3 (Reinhold et al., 2012; Figure 1). RECQ1
mRNA expression in the NCI-60 panel is shown in Figure 1A
both as average transcript intensity values and as the average
z score that allows a better comparison of relative expression.
Noticeably, the NCI-60 cell lines exhibit a wide spectrum of
RECQ1 expression with transcript level values ranging from both
lower and higher than the mean (Figure 1B). Cell lines melanoma
LOXIMVI and central nervous system SF_268 showed the highest
RECQ1 mRNA levels, whereas ovarian cancer cell lines OVCAR_4
and SK_OV_3 showed the lowest (Figure 1B). Nine out of the
10 melanoma cell lines and 4 out of 6 central nervous system
cell lines expressed high RECQ1 mRNA (Figure 1B). SK_MEL_5
cells were the only melanoma cells within the NCI-60 panel with
lower RECQ1 transcript levels. The lung and renal cell lines were
most variable in RECQ1 expression and the ovarian cell lines
expressed lowest levels of RECQ1 transcript. It remains to be
tested whether RECQ1 transcript levels correlate with the protein
level, but a statistically significant correlation with DNA copy
number (Pearson’s correlation R = 0.38; P = 0.003) was observed
with the estimated RECQ1 DNA copy number ranging from 3.67
for lung cancer cell line NCI_H322M to 1.35 in ovarian cancer
cell line SK_OV_3. Expression profiles of five known RecQ family
genes across the NCI-60 panel revealed no significant correlation
of RECQ1 mRNA expression with WRN, BLM, or RECQL5;
3http://discover.nci.nih.gov/cellminer/
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FIGURE 1 | RECQ1 transcript levels in the NCI-60 human tumor cell
lines. (A) Table of average intensity (determined from log 2 intensity
values from Affymetrix microarrays) and their combined z-score means
presented in descending order. (B) Scatter plot depicting the distribution
of RECQ1 transcript levels across the NCI-60. The numerical series
(1-to-60) for the cell lines from panel (A) correspond to the x-axis. Cell
lines from the central nervous system (shown in yellow) and melanoma
(shown in pink) displayed higher transcript levels of RECQ1, while ovarian
cancer cell lines (shown in blue) displayed the least. (C) Cross-correlation
among RecQ family. Pearson’s correlation coefficients between
transcripts of the known five RecQ homologs in the NCI-60. Only
significant correlation of RECQ1 in the NCI-60 is with the RECQL4
transcripts. Processing and normalization of transcript expression data
from the NCI-60 has been described previously (Reinhold et al., 2012).
Normalization of Affymetrix HG-U95, HG-U133, HG-U133 plus 2.0 and
Affy HuEx 1.0 is done by GC robust multi-array average (GCRMA). Data
is accessible at http://discover.nci.nih.gov by using RECQL (RECQ1) as
input in Cellminer.
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however, RECQ1 expression displayed significant inverse corre-
lation with RECQL4 (Figure 1C).
Recent studies using the NCI-60 panel have shown that the
genes whose expression at the mRNA level is correlated over
diverse cell lines are likely to function together in a molecular
network regulating these processes (Kohn et al., 2012, 2014).
We postulated that the ability of RECQ1 to promote tumor cell
migration and invasion involves changes in expression of specific
genes that are critical to these processes. Using the CellMiner
NCI-60 analysis tools, we searched for genes that were signif-
icantly correlated with RECQ1-expression across the NCI-60
panel and had established functions in cell migration and invasion
(Figure 2A). Notably, RECQ1 expression displayed significant
positive correlation with mesenchymal differentiation markers
vimentin, N-cadherin, and fibronectin (VIM, FN1, and CDH2),
and transcription factors that promote these processes (TWIST,
SNAI2, and ZEB2). Furthermore, RECQ1 expression correlated
significantly and negatively with genes maintaining cellular struc-
tural integrity (KRT8) and epithelial marker E-cadherin (CDH1).
Correlation of the mRNA transcript levels of RECQ1 with VIM
and CDH1 across the NCI-60 tumor cell lines is depicted in
Figure 2B. The NCI-60 gene expression profile for CDH1 is
inversely correlated to that of the gene VIM which is considered
as a hallmark of mesenchymal-like conversion of epithelial cells in
carcinomas (Zeisberg and Neilson, 2009; Kohn et al., 2014).
PREDICTIVE AND PROGNOSTIC POTENTIAL OF RECQ1
EXPRESSION IN CANCER
Predictions from in silico analysis across the NCI-60 panel support
previously reported overexpression of RECQ1 in various cancers
and indicate RECQ1 expression to be especially significant in
tumors of central nervous system origin and melanoma. Evi-
dently, RECQ1 is highly expressed in human brain glioblas-
toma relative to control brain tissues and its depletion affects
proliferation of glioblastoma cells and causes an increased level
of DNA damages (Mendoza-Maldonado et al., 2011). Exam-
ining RECQ1 gene expression using the ONCOMINE mRNA
microarray database4 revealed that RECQ1 is significantly upreg-
ulated in brain and central nervous system tumors, including
glioblastoma, when compared to normal tissue. Overexpression
of DNA repair genes is associated with metastasis in melanomas
(Kauffmann et al., 2008), and the expression levels of RECQ1
significantly correlated with DNA repair genes displaying func-
tional network which are commonly overexpressed in tumors
with poorer prognosis in melanoma (Jewell et al., 2010). Given
the demonstrated roles of RECQ1 in repairing DNA damage
caused by chemotherapeutic agents such as ionizing radiation,
camptothecin, and temozolomide, overexpression of RECQ1 may
provide a survival advantage to melanoma cells by promoting
the ability of cancer cells to tolerate genotoxic stress. In contrast,
WRN and RECQL4 may have a tumor suppressor function in
melanoma since melanoma has been reported in patients with
loss of function mutations in these RecQ proteins (Howell and
Bray, 2008; Monnat, 2010). Notably, within the RecQ family,
RECQ1 expression correlated significantly and negatively with
4www.oncomine.org
RECQL4 across the NCI-60 panel. Lao et al. (2013) have recently
shown that the expression of BLM and RECQL4 is increased in
primary colorectal cancer whereas expression levels of RECQ1
and RECQL5 are decreased. Consistent with the observation
in primary colorectal cancer patient samples, low expression
of RECQ1 and significantly high expression of RECQL4 were
observed in colorectal cancer cell lines as compared to normal
colonic mucosa indicating the feasibility of using cell lines to study
the functional consequences of alterations in the expression levels
of the RecQ helicases (Lao et al., 2013).
RecQ helicases contribute multiple biochemical activities to
various DNA repair processes and loss of their functions leads
to increased DNA damage, genomic instability, and enhanced
sensitivity to certain chemotherapeutic agents (Brosh, 2013).
Therefore, altered expression of RecQ helicases may be useful in
predicting patient’s response to these DNA damaging drugs used
for treatment of cancer. Indeed RECQ1 expression correlated with
cisplatin resistance in oral squamous cell carcinoma (Zhang et al.,
2006) and the depletion of RECQ1 significantly augmented the
in vivo anticancer effects of the drug cis-platinum (II) diammine
dichloride (Arai et al., 2011). This is consistent with the fact that
cisplatin and related platinum drugs induce inter-strand cross
links in DNA that impair progression of replication forks and
RECQ1 helicase functions are important to restore productive
DNA replication (Sami and Sharma, 2013). However, RECQ1
expression was found to be elevated in ovarian cancer cells
that were sensitive to carboplatin as compared to those which
were carboplatin-resistant (Peters et al., 2005) indicating complex
mechanisms of platinum resistance (Stewart, 2007). Thus, a better
correlation of RECQ1 expression with the molecular characteris-
tics and heterogeneity of cancer needs to be established in order
to test the use of RECQ1 as a potential biomarker.
In addition to unlimited proliferative potential, a tumor cell
must acquire the ability to migrate and invade normal tissues to
become fully malignant (Hanahan and Weinberg, 2011). Inva-
sion of tumor cells and metastatic spread to distant organs
relies on complex molecular interactions including diminished
epithelial characteristics and enhanced mesenchymal attributes
(Kalluri and Weinberg, 2009). RECQ1 expression across the NCI-
60 panel significantly correlated with a loss of the epithelial
marker CDH1 and acquisition of expression of the mesenchymal
markers including VIM. Correlation with VIM in the NCI-60
panel raises the question whether RECQ1 expression is associ-
ated with the epithelial to mesenchymal transition (EMT) which
is among the central mechanisms to induce invasiveness and
metastasis of tumors. Indeed, RECQ1-depletion decreased cell
migration and invasion in cervical adenocarcinoma HeLa and
breast cancer MDA-MB-231 cell lines (Li et al., 2014). Similarly,
RECQ1 silencing in oral squamous cell carcinoma SCC-9 cells
downregulated the expression level of immunosuppressive factors
that are necessary for regulating the migration of tumor cells
(Tao et al., 2014). Collectively these results propose that RECQ1
may contribute to tumor progression by regulating key genes
that promote cancer cell migration, invasion, and metastasis. It
is plausible that similar to what has been shown for a few other
proteins involved in DNA damage response and repair, RECQ1
participates in transcription regulation either by binding directly
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FIGURE 2 | Continued
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FIGURE 2 | RECQ1 expression in the NCI-60 panel correlates with
markers of tumor progression. (A) Significant correlations of RECQ1 with
select genes involved the cell invasion, migration, and metastasis. The
numbers in the table are expression profile correlations for expression of
gene pairs in the NCI-60 panel. EMT, epithelial to mesenchymal transition; (B)
RECQ1 expression is highly correlated with the mesenchymal marker
vimentin. Comparison of expression profiles for RECQ1, VIM (vimentin), and
CDH1 (E-cadherin) across the NCI-60 cell lines. Mean-centered transcript
z-cores are plotted on the x-axis; bars to the right show increased expression,
bars to the left show decreased expression relative to the expression mean.
The cell lines on the y -axis are grouped by tissue of origin. BR, breast; CNS,
central nervous system; CO, colon; LE, leukemia; ME, melanoma; LC, lung
cancer; OV, ovarian; PR, prostrate; RE, renal. Data was generated querying
RECQL (RECQ1) as input in Cellminer (http://discover.nci.nih.gov/cellminer/).
to DNA or through interaction with specific transcription factors
(Featherstone and Jackson, 1999; Mullan et al., 2006; Kraus, 2008;
Jaehnig et al., 2013; Broustas and Lieberman, 2014). A systematic
investigation of RECQ1-regulated transcriptome may uncover
the gene networks regulated by RECQ1 in the context of cancer
progression.
Increased expression of several DNA repair proteins has been
correlated with cellular invasiveness in cancer (Mitra et al., 2009;
Barbano et al., 2011; Martinez-Marignac et al., 2011; Yuan et al.,
2012); however, little effort has been made thus far to determine
any role of RecQ helicase homologs in tumor progression and
metastasis. Understanding the role of RECQ1 in conferring pro-
liferative and invasive phenotype to cancer cells could be use-
ful in developing therapeutic strategies to block primary tumor
progression and metastases. Functional evidence from RECQ1
silencing, and the projected correlation with VIM expression in
the NCI-60 panel implies an association of RECQ1 with more
aggressive disease (Zeisberg and Neilson, 2009). Future studies
should examine whether RECQ1 mRNA and/or protein levels can
predict invasion and metastatic potential of a tumor. Predictions
from large human cancer cell line panels that capture tumor het-
erogeneity, such as NCI-60, and the availability of clinically and
molecularly annotated patient tumor datasets for multiple tumor
types, such as TCGA, should provide additional opportunities
to test the significance of RECQ1 in developing new in vitro
preclinical models for cancer detection and treatment.
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